Gold BD, Goodwin B, Davis K, Sweeney C, Ziemiecki R, Jiang J, Fan T, Boules M, Chen ST, Katzka DA. Satisfaction with and adherence to off-label corticosteroids in adolescents and adults with eosinophilic esophagitis results of a web-based survey in the United States. J Clin Gastroenterol. 2024 May 15. doi: 10.1097/MCG.0000000000002006
Planas A, Simo-Servat O, Hernandez C, Ortiz-Zuniga A, Marsal JR, Herance JR, Ferreira-Gonzalez I, Simo R. Diabetic retinopathy and skin tissue advanced glycation end products are biomarkers of cardiovascular events in type 2 diabetic patients. J Pers Med. 2021 Dec 10;11(12):1344.
Brunette CA, Dong OM, Vassy JL, Danowski ME, Alexander N, Antwi AA, Christensen KD. A cost–consequence analysis of preemptive SLCO1B1 testing for statin myopathy risk compared to usual care. J Pers Med. 2021 Oct 31;11(11):1123. doi: 10.3390/jpm11111123
Sperber NR, Dong OM, Roberts MC, Dexter P, Elsey AR, Ginsburg GS, Horowitz CR, Johnson JA, Levy KD, Ong H, Peterson JF, Pollin TI, Rakhra-Burris T, Ramos MA, Skaar T, Orlando LA. Strategies to integrate genomic medicine into clinical care: evidence from the IGNITE network. J Pers Med. 2021 Jul 8;11(7):647. doi: 10.3390/jpm11070647
Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Davis KL, Mitra D, Medjedovic J, Beam C, Rustgi V. Direct economic burden of chronic hepatitis c virus in a United States managed care population. J Clin Gastroenterol. 2011 Feb 1;45(2):e17-24.